Skip to main content
. 2021 Feb 16;10(2):411. doi: 10.3390/cells10020411

Figure 2.

Figure 2

Differences in interleukin-10 (IL-10) serum or plasma levels as well as percentages of CD19+CD24hiCD38hi Bregs and IL-10 production in PBMCs of Ps, BMMCs of MM, PBMCs of RRMM patients, and PBMCs of HVs. Analyses between two groups were performed using Mann–Whitney U-test while topmost p values were obtained from Kruskal-Wallis test. (A) Significantly higher IL-10 serum levels in Ps patients vs. IL-10 plasma levels of HVs (p < 0.0001) and plasma of MM patients vs. HVs (p < 0.0001). (B) Flow cytometry analysis of mean fluorescence intensities (MFI) of CD19+CD24hiCD38hi IL-10+ in HVs, Ps, and MM patients demonstrated increased production of IL-10 in Ps patients in comparison with HVs (p < 0.0001). Cells were surface-stained with anti-CD19-Pe-Cy7, anti-CD24-APC, anti-CD38-FITC, and intracellularly with IL10-PE antibodies. (C) Chart showing significantly elevated percentages of CD19+CD24hiCD38hi Bregs in PBMCs of RRMM patients in comparison with HVs (p = 0.0006) as well as vs. PBMCs of MM (p = 0.0004) and no difference between PBMCs of Ps patients vs. HVs. (D) The percentages of CD19+CD24hiCD38hi according to PASI stage system in Ps patients. (E) The percentages of Breg cells in the different clinical ISS stages in MM patients showed a significant decrease of Bregs level in ISS stage III in comparison with ISS stage I (p = 0.0233). (F) Assessment of the CD19+CD24hiCD38hi IL-10 MFI of MM patients according to ISS stages demonstrated significantly elevated intensity in ISS stage III vs. ISS stage I (p = 0.0084) and ISS stage II (p = 0.01).